Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Digera muricata, commonly known as Tartara or False Amaranth, is an edible herb widely utilized in traditional medicine across Africa and Asia. Recent pharmacological research has focused on its phytosterol-rich extracts, particularly those containing sitosterol, for their potential in treating atherosclerosis and inflammatory conditions. The extract demonstrates significant anti-atherogenic activity by modulating macrophage polarization, reducing oxidative stress (ROS and nitric oxide), and inhibiting lipid peroxidation. Mechanistically, it downregulates pro-inflammatory and pro-atherogenic mediators such as iNOS, COX-2, MMP9, and various cytokines (IL-6, IL-1β), while upregulating anti-atherogenic factors like PPARγ and MRC1. Additionally, it helps maintain mitochondrial membrane potential and cell membrane integrity in macrophages challenged by atherogenic stimuli.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on digera muricata.